News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Proteome Sciences PLC H1 Pretax Loss Narrows; Sees Licensing for TMT by Year-End
October 2, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - Proteome Sciences PLC posted a narrower first half pretax loss and higher revenues and said it is "well set" to provide strong and sustainable revenue stream.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Layoff Tracker
Novo workforce down 13,000
September 23, 2026
·
95 min read
·
BioSpace Editorial Staff
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
·
2 min read
·
Tristan Manalac
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
·
2 min read
·
Jef Akst
Manufacturing
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
September 22, 2026
·
2 min read
·
Nick Paul Taylor
